What is the Fiscal Year for Intra-Cellular Therapies?
Date: November 13, 2026
Intra-Cellular Therapies's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
New Jersey, United States
Industry
Pharmaceutical Manufacturing
Stock Symbol
ITCI
Description
Intra-Cellular Therapies, Inc., a Johnson & Johnson company, is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. Follow us at Johnson & Johnson Innovative Medicine to discover how we’re working together to become the number one neuroscience company worldwide. [https://www.linkedin.com/company/jnjinnovativemedicine/home/]
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Intra-Cellular Therapies and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.